title: A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism.
abstract: BACKGROUND
  Approximately 7-10% of patients with unprovoked VTE will be diagnosed with cancer within 12 months. Although cancer screening has been proposed in these patients, the optimal strategy remains unclear. In a pilot study, we prospectively investigated the use of FDG-PET/CT to screen for occult malignancy in 40 patients with unprovoked VTE.
  
  
  METHODS
  Patients were initially screened for occult malignancy with a focused history, physical, and laboratory evaluation. Patients underwent whole body FDG-PET/CT and were followed for up to two years for a new diagnosis of cancer. The total costs of using FDG-PET/CT as a comprehensive screening strategy were determined using 2010 Medicare reimbursement rates.
  
  
  RESULTS
  Completion of FDG-PET/CT imaging was feasible and identified abnormal findings requiring additional evaluations in 62.5% of patients. Occult malignancy was evident in only one patient (cancer incidence 2.5%) and FDG-PET/CT imaging excluded malignancy in the remainder of patients. No patients with a negative FDG-PET/CT were diagnosed with malignancy during an average (±SD) follow-up of 449 (±311) days. The use of FDG-PET/CT to screen for occult malignancy added $59,151 in total costs ($1,479 per patient). The majority of these costs were due to the cost of the FDG-PET/CT ($1,162 per patient or 78.5% of total per-patient costs).
  
  
  CONCLUSIONS
  FDG-PET/CT may have utility for excluding occult malignancy in patients with unprovoked VTE. The costs of this comprehensive screening strategy were comparable to other screening approaches. Larger studies are needed to further evaluate the utility and cost-effectiveness of FDG-PET/CT as a cancer screening strategy in patients with unprovoked VTE.
authors.affiliation: Division of General Internal Medicine, University of Utah, Salt Lake City, Utah 84132, USA. matthew.rondina@hsc.utah.edu
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Rondina
authors.forename: Nathan
authors.initials: N
authors.lastname: Wanner
authors.forename: Robert C
authors.initials: RC
authors.lastname: Pendleton
authors.forename: Larry W
authors.initials: LW
authors.lastname: Kraiss
authors.forename: Russell
authors.initials: R
authors.lastname: Vinik
authors.forename: Guy A
authors.initials: GA
authors.lastname: Zimmerman
authors.forename: Marta
authors.initials: M
authors.lastname: Heilbrun
authors.forename: John M
authors.initials: JM
authors.lastname: Hoffman
authors.forename: Kathryn A
authors.initials: KA
authors.lastname: Morton
mesh_terms: D000328:Adult; D000368:Aged; D003362:Cost-Benefit Analysis; D055088:Early Detection of Cancer; D005240:Feasibility Studies; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D007349:Insurance, Health, Reimbursement; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000379:methods*; D006278:Medicare / Q000191:economics; D008875:Middle Aged; D064847:Multimodal Imaging / Q000191:economics; D009369:Neoplasms / Q000097:blood / Q000150:complications / Q000000981:diagnostic imaging* / Q000191:economics; D010865:Pilot Projects; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D011446:Prospective Studies; D019275:Radiopharmaceuticals / Q000191:economics; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D014481:United States; D014589:Utah; D054556:Venous Thromboembolism / Q000097:blood / Q000191:economics / Q000209:etiology*; D051598:Whole Body Imaging / Q000191:economics
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18